Crescita Therpeutc (CTX) AI Stock Analysis

• Market Cap: C$8.90M
• Dividend Yield: N/A
• Average Volume (3M): 11.51K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.20
• Revenue Growth: 1.14%
• EPS Growth: -36.66%
• Country: CA
• Employees: 80
• Sector: Healthcare
• Sector Strength: 40
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.05
• Shares Outstanding: 18,939,262
• 10 Day Avg. Volume: 10,370
• 30 Day Avg. Volume: 11,511
• PEG Ratio: 0.21
• Price to Book (P/B): 0.62
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -27.92
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: C$0.50
• Price Target Upside: 6.38% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 54 Neutral
• Price Target: C$0.50 ▲(6.38%Upside)

Crescita Therapeutics' overall score is primarily affected by its financial performance and valuation challenges. Positive shareholder support and strategic initiatives provide some balance, but the lack of earnings growth and technical weakness weigh heavily.

Crescita Therpeutc Business Overview & Revenue Model

Company Description

Crescita Therapeutics Inc., a dermatology company, provides non-prescription skincare products and prescription drug products in Canada, the United States, and internationally. The company operates through three segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. It owns proprietary platform technologies, including MMPE and DuraPeel for the development of topicals containing cannabis and hemp. The company's prescription products include Pliaglis, a topical local anesthetic cream that provides dermal analgesia on intact skin prior to superficial dermatological procedures; CTX-101, a Phase III topical formulation utilizing a corticosteroid in combination with MMPE technology to treat plaque psoriasis; CTX-102, a Phase I topical formulation utilizing MMPE technology to treat an undisclosed dermatological skin condition; and dermatology products in pre-clinical formulation utilizing MMPE technology for prescription treatments of skin diseases. Its non-prescription skincare products comprise skincare products, such as facial creams, cleansers, exfoliants, masks, serums, and suncare products for aging, acne, rosacea, pigmentation, dehydration, and sensitivity under the Laboratoire Dr Renaud brand; a line of dermocosmetic products for anti-aging medical procedures under the Pro-Derm brand; a line of products to target and treat various skincare concerns under the Alyria brand; and skincare products primarily for the Asian consumers under Dermazulene brand, as well as NCTF 135 HA, a skin revitalization solution primarily used for the improvement of skin quality and fine lines. The company has a development and licensing agreement with Sundial Growers Inc. to develop cannabis; a commercialization license agreement with Cantabria Labs Inc.; and a development and commercialization license agreement with Taro Pharmaceuticals Inc. Crescita Therapeutics Inc. was incorporated in 2016 and is headquartered in Laval, Canada.

How the Company Makes Money

Crescita Therapeutics Inc. generates revenue through multiple streams, primarily from the sale of its dermatological products in both prescription and over-the-counter markets. The company also earns income through licensing agreements and partnerships, where it licenses its patented transdermal delivery technologies and formulations to other pharmaceutical companies. Additionally, Crescita benefits from contract manufacturing services, producing dermatological products for third parties. Key factors contributing to its earnings include its proprietary technologies, strategic collaborations, and the expanding market for skincare solutions.

Crescita Therpeutc Financial Statement Overview

Summary

Crescita Therapeutics faces declining revenues and profitability challenges, with a negative EBIT and net income margins. However, it maintains a strong balance sheet with low leverage and improved cash flow management, despite some inconsistencies.

Income Statement

Crescita Therapeutics has experienced a declining revenue trend from 2022 to 2024, with total revenue decreasing by 16.8% from 2022 to 2023 and further by 11.2% from 2023 to 2024. The company has negative EBIT and net income margins, indicating challenges in managing operating expenses and generating profits. Gross profit margin fell from 55.98% in 2022 to 49.06% in 2024, showing pressure on profitability.

Balance Sheet

The company's balance sheet remains fairly stable, with a manageable debt-to-equity ratio of 0.05 in 2024, suggesting low financial leverage. However, stockholders' equity has decreased over the years. The equity ratio of 72.71% in 2024 reflects a solid capital structure. However, the decline in total assets from 2020 to 2024 indicates a contraction in the company's asset base.

Cash Flow

There has been a positive trend in operating cash flow from 2023 to 2024, improving free cash flow from negative to positive territory. The free cash flow to net income ratio is favorable, indicating efficient cash management despite net losses. However, fluctuations in free cash flow growth and operating cash flow indicate inconsistencies in cash generation.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	19.58M	17.52M	23.52M	16.77M	15.64M
Gross Profit	9.61M	10.36M	13.18M	10.01M	11.27M
EBITDA	-1.33M	45.00K	2.09M	598.00K	2.26M
Net Income	-2.75M	-1.99M	862.00K	-1.10M	37.00K
Balance Sheet
Total Assets	21.78M	24.60M	28.48M	28.92M	26.83M
Cash, Cash Equivalents and Short-Term Investments	9.27M	9.38M	8.24M	11.33M	14.28M
Total Debt	834.00K	1.25M	1.61M	2.87M	1.23M
Total Liabilities	5.95M	5.78M	7.39M	8.40M	5.70M
Stockholders Equity	15.83M	18.82M	21.10M	20.53M	21.13M
Cash Flow
Free Cash Flow	1.54M	1.94M	-1.25M	-1.94M	5.55M
Operating Cash Flow	2.73M	2.08M	-1.02M	-1.60M	5.61M
Investing Cash Flow	-2.02M	-133.00K	-290.00K	-846.00K	-59.00K
Financing Cash Flow	-861.00K	-782.00K	-1.85M	-500.00K	-476.00K

Crescita Therpeutc Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.47
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:CTX, the sentiment is Negative. The current price of 0.47 is below the 20-day moving average (MA) of 0.49, below the 50-day MA of 0.50, and below the 200-day MA of 0.56, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 46.16 is Neutral, neither overbought nor oversold. The STOCH value of 25.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:CTX.

Crescita Therpeutc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CTX	54 Neutral	C$8.90M	―	-18.52%	―	1.14%	-36.66%
MPH	54 Neutral	C$11.58M	―	-8.79%	―	-0.29%	-53.83%
Sector *	52 Neutral	$7.37B	-0.04	-63.81%	2.59%	16.40%	<0.01%
RVV	46 Neutral	C$8.37M	―	-50.76%	―	―	-4.84%
MVMD	35 Underperform	C$8.81M	―	-44.58%	―	-48.33%	47.56%
AQS	21 Underperform	C$663.17K	―	43.02%	―	129.21%	26.79%

Crescita Therpeutc Corporate Events

Crescita Therapeutics Reports Positive Shareholder Meeting Outcomes

Crescita Therapeutics Inc. announced the results of its Annual General and Special Meeting of Shareholders, highlighting the election of directors, reappointment of external auditors, and approval of the continuation of its Shareholder Rights Plan. The meeting results indicate strong shareholder support for the company’s leadership and strategic initiatives, which could positively impact Crescita’s market position and stakeholder confidence.

Crescita Therapeutics Regains Pliaglis Rights After Ending Croma Agreement

Crescita Therapeutics has mutually terminated its licensing agreement with Croma Pharma GmbH for the commercialization of Pliaglis in several European and South American countries. This strategic decision allows Crescita to regain control over Pliaglis’s development and commercialization rights in these territories and explore new partnerships, while Croma rationalizes its product portfolio and pays Crescita €575,000.

Crescita Therapeutics Reports Decline in Q1 2025 Financial Results

Crescita Therapeutics reported a decline in its financial performance for the first quarter of 2025, with revenue dropping to $3,537,000 from $4,996,000 in the same period the previous year. The decrease was attributed to the timing of order fulfillment in the Manufacturing segment. Despite the current downturn, the company anticipates improved performance in upcoming quarters due to larger scheduled orders. Crescita is maintaining a disciplined approach to capital deployment, balancing growth investments with financial stability.